Insilico Medicine Highlights AI-Driven Sustainability at NY Climate Week
核心洞察
Insilico Medicine (搜索)'s CEO, Alex Zhavoronkov, presented AI-driven sustainability efforts at the AWS Climate Tech & AI Forum during NY Climate Week.
Insilico is exploring AI applications in agrochemistry, hydrogen storage, and CO2 capture, supported by partners like Syngenta (搜索) and Saudi Aramco (搜索).
Insilico Medicine (搜索) has nominated 19 preclinical candidates since 2021 and received IND approval for 9 molecules using its Pharma.AI platform.
Insilico Medicine (搜索) highlighted its AI-driven sustainability efforts at the AWS Climate Tech & AI Forum during NY Climate Week. Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, presented insights on AI's role in sustainability, covering drug discovery, productive longevity, and environmental applications. The forum, held annually, addresses the urgent need for innovative climate solutions, emphasizing the potential of generative AI and machine learning.
AI for Sustainable Development
Insilico Medicine (搜索) has been exploring AI-powered sustainable development, venturing into areas like agrochemistry, hydrogen storage, and CO2 capture. These efforts are supported by partners including Syngenta (搜索) and Saudi Aramco (搜索). The company's work aligns with the theme of NY Climate Week, "It’s Time," underscoring the urgency for immediate and ambitious climate action.
Pharma.AI Platform
Insilico Medicine (搜索) first described the concept of using generative AI for novel molecule design in 2016. This work laid the foundation for the Pharma.AI platform, a generative AI-powered solution spanning biology, chemistry, and clinical development. Powered by Pharma.AI, Insilico has nominated 19 preclinical candidates in its portfolio of over 30 assets since 2021 and has received IND approval for 9 molecules.
Clinical Validation of AI-Driven Drug Discovery
In early 2024, Insilico published a paper in Nature Biotechnology presenting the R&D journey from AI algorithms to Phase II clinical trials for ISM001_055, an AI-discovered target and AI-designed structure. Preliminary results from a Phase IIa trial (NCT05938920) showed dose-dependent response in forced vital capacity (FVC) after 12 weeks of dosage.